MG
ATOS icon

Michael Gelband’s Atossa Therapeutics ATOS Stock Holding History

Michael Gelband’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-901
Closed -$11K – 1523
2025
Q2 		$11K Buy
+901
New +$10.8K ﹤0.01% 1394
2024
Q2 		– Sell
-1,731
Closed -$47K – 1521
2024
Q1 		$47K Buy
+1,731
New +$27.8K ﹤0.01% 1435
2022
Q2 		– Sell
-1,530
Closed -$29K – 1921
2022
Q1 		$29K Sell
1,530
-1,234
-45% -$25.1K ﹤0.01% 2093
2021
Q4 		$66K Sell
2,764
-6,569
-70% -$240K ﹤0.01% 2006
2021
Q3 		$456K Buy
+9,333
New +$543K 0.01% 1449

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Michael Gelband's ATOS Position: Q3 2025 in Review

Michael Gelband sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 901 shares — an estimated $11K sold.

Michael Gelband first reported a position in ATOS in Q3 2021 and held it in 5 quarters. The position peaked at $456K in Q3 2021. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Michael Gelband reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Michael Gelband sold 901 Atossa Therapeutics shares in Q3 2025, an estimated $11K.
  • Michael Gelband first reported a position in Atossa Therapeutics in Q3 2021 and held it in 5 quarters.
  • Michael Gelband's Atossa Therapeutics position peaked at $456K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.